Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals (NGM) is a clinical-stage biopharmaceutical company pioneering novel biologic therapies through its integrated drug discovery platform. This page serves as the definitive source for verified updates on the company's research advancements, clinical developments, and strategic milestones.
Investors and industry professionals will find timely updates across key areas including clinical trial progress, regulatory filings, partnership announcements, and financial reporting. Our curated collection ensures access to primary-source materials while maintaining compliance with financial disclosure standards.
The news archive features categorized updates on therapeutic developments in NGM's core focus domains: cardio-metabolic disorders, liver diseases, and emerging oncology programs. Each entry connects to the company's biology-driven approach, emphasizing its protein engineering capabilities and target validation methodologies.
For consistent monitoring of NGM's innovative pipeline, bookmark this page or check back regularly. Subscribers to our financial updates service receive automated alerts when new material disclosures are published.
NGM Biopharmaceuticals (NASDAQ: NGM) stockholders are notified of a proposed $6 million settlement in a class action lawsuit related to the company's take-private transaction with The Column Group, LP. The lawsuit involves shareholders who received $1.55 per share in cash during the April 5, 2024 transaction closing or who dissented from it.
A settlement hearing is scheduled for October 21, 2025, where the Court will consider the settlement's fairness, certification of the Class, and approval of attorneys' fees. Eligible Class Members will receive pro rata payments from the Net Settlement Fund based on their number of eligible shares, with no claim form required.
The deadline for objections to the settlement is October 7, 2025. The settlement will be administered by A.B. Data, Ltd., with Equity Litigation Group LLP serving as Plaintiff's Counsel.
Xaira Therapeutics has appointed Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. Jonker, a biotech industry veteran with over two decades of leadership experience, will help scale Xaira's AI-enabled drug discovery platform and oversee operational functions.
Jonker's experience includes serving as CEO of Belharra Therapeutics and Ambys Medicines, and as President of NGM Biopharmaceuticals (NASDAQ: NGM). At NGM, he expanded the therapeutic pipeline and formed a strategic partnership with Merck. The appointment comes as Xaira advances its AI-driven drug discovery initiatives, recently publishing X‑Atlas/Orion, the largest publicly available genome-wide Perturb‑seq dataset.
